Use of the 46/1 haplotype to model JAK2 V617F clonal architecture in PV patients: Clonal evolution and impact of IFN treatment

Leukemia

Volumn 28, Issue 2, 2014, Pages 460-463

  Hasan, S ^a,b   Cassinat, B ^c   Droin, N ^a,b   Le Couedic, J P ^a,b   Favale, F ^a,b   Monte Mor, B ^a,b   Lacout, C ^a,b   Fontenay, M ^c   Dosquet, C ^d   Chomienne, C ^c,e   Solary, E ^a,b   Villeval, J L ^a,b   Casadevall, N ^a,f   Kiladjian, J J ^c   Vainchenker, W ^a,b   Plo, I ^a,b  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d Institut Cochin   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; JANUS KINASE 2;

ALLELE; CELL DIFFERENTIATION; CHROMOSOME 9; CHROMOSOME 9P; CLONAL EVOLUTION; GENOTYPE; HAPLOTYPE; HEMATOPOIETIC STEM CELL; HOMOLOGOUS RECOMBINATION; HOMOZYGOSITY; LETTER; MUTATION; MYELOID DENDRITIC CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY; WILD TYPE;

ALLELES; CLONAL EVOLUTION; HAPLOTYPES; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-ALPHA; JANUS KINASE 2; MODELS, BIOLOGICAL; MUTATION; POLYCYTHEMIA VERA;

EID: 84893786554     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.303     Document Type: Letter

References (15)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
2. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11: 546-554.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
5. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41: 446-449.
6. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41: 455-459.
7. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450-454.
8. Anand S, Stedham F, Beer P, Gudgin E, Ortmann CA, Bench A et al. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 2011; 118: 177-181.
9. Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, Larbret F et al. The JAK2 617V4F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007; 110: 1013-1021.
10. Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood 2012; 120: 2704-2707.
11. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115: 3589-3597.
12. Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood 2012; 120: 166-172.
13. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009; 113: 4829-4833.
14. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 2013; 122: 893-901.
15. Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol 2010; 38: 472-480.